The high court’s brief order affirms a Chancery Court ruling from July 2024 that found the lawsuit failed to show the pharmaceutical company was Viela’s controlling shareholder at the time of the 2021 sale, or that it had materially misled or omitted facts in communications with investors.
- Former Viela shareholder Stephen Sciannella alleged AstraZeneca had threatened to sell its 26.7% stake in Viela unless the biotech firm was quickly acquired
- Horizon Therapeutics Plc paid ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.